A COVID-19 Vaccine: What’s Been Done and What’s to Come • Maiya Hossain

A COVID-19 Vaccine: What’s Been Done and What’s to Come By Maiya Hossain

The coronavirus (COVID-19) pandemic has completely taken the world aback, forcing individuals to alter their usual ways of life. From abruptly transitioning to Zoom classes in March to requiring masks in virtually all public spaces, COVID-19 has affected all facets of society, which has paved the way for what some dub the “new normal.” However, it’s clear that many people are dissatisfied with these unprecedented circumstances, as they have led to significant lifestyle restrictions, record-high unemployment levels, and negative mental health implications. With cases in the US at an all-time high nine months after the pandemic was declared a national emergency, many are left wondering: when, if ever, will life go back to normal again?

The answer greatly depends on the development and distribution of a coronavirus vaccine. This process usually takes place over the span of several years. However, the US government, in partnership with the private sector, has initiated a multibillion-dollar plan known as Operation Warp Speed (OWS), which aims to accelerate the production and delivery of safe and effective COVID-19 vaccines to the general public. In June 2020, the White House named five vaccine candidates that would most likely meet the timeline of OWS. These include Moderna’s mRNA-1273, AstraZeneca and Oxford University’s AZD-1222, Johnson & Johnson’s JNJ-78436735, Merck’s multiple candidates, and Pfizer and BioNTech’s BNT-162b2.

Among the first to announce promising results related to a coronavirus vaccine was the American pharmaceutical company, Pfizer, along with its German partner, BioNTech. Their vaccine employs mRNA technology, in which the body’s cells translate genetic information from an mRNA sequence to produce antigens in the form of the SARS-CoV-2 full-length spike glycoprotein (S).

These antigens are subsequently exhibited on the surface of the body’s cells, initiating an immune response that enables the production of antibodies against the glycoproteins. After successful early clinical trials in animals, Pfizer and BioNTech proceeded to Phase 3 in July 2020. This stage is especially vital in vaccine development, as it tests the efficacy of the immunization on a large population. In Phase 3 of the companies’ clinical trials, half of the 44,000 participants received the vaccine, and the other half received a placebo of saltwater. Out of the 44,000 participants in the study, 94 became sick.7 Although it was not indicated how many of the sick participants had received the vaccination, Pfizer released preliminary data based on these results on November 9, indicating a vaccine efficacy rate above 90%. At

the time of this declaration, however, the study had not yet been concluded. Only 94 COVID-19 cases had been identified, but a total of 164 cases needed to be detected in order to complete the trial.

Pfizer and BioNTech ultimately became the first companies to release complete results of their coronavirus vaccine trials after they officially concluded Phase 3 of their study on November 18. They announced that their vaccine, BNT-162b2, turned out to be 95% effective against COVID-19, an with a pandemic that has taken the lives of more than 1.5 million people. The US Food and Drug Administration (FDA) standards for a successful COVID-19 vaccine require a 50% efficacy rate, and Pfizer and BioNTech’s BNT-162b2 clearly exceeds this threshold by a wide margin. Thus, on November 20, the companies submitted an emergency use authorization request to the FDA, in addition to submitting other rolling submissions worldwide, including Australia, Canada, Europe, Japan, and the United Kingdom. The US FDA plans to review the authorization of this vaccine on December 10. Meanwhile, on December 2, Britain became the first country in the world to authorize the use of Pfizer and BioNTech’s COVID-19 vaccine.

These advancements undoubtedly mark major milestones in the midst of seemingly never-ending coronavirus chaos. However, the companies’ vaccine poses significant logistical challenges in terms of reaching patients. One major obstacle is temperature—the vaccine must be kept frozen at -70oC, making distribution much less convenient and much more expensive. The reason as to why this vaccine must be kept ultracold goes back to its mRNA technology—mRNA is fragile and easily degraded. To ensure that the mRNA is intact when it reaches patients, it must be stored at an extremely low temperature. This emerges as a serious challenge to an essential part of controlling the pandemic, as the availability of transportation with freezers is limited. The finite supply of freezer trucks, trains, and planes is already being used to transport other goods and

Wikimedia Commons

Front line health care workers are being prioritized to receive the COVID-19 vaccine due to their frequent exposure to the disease.

“[Pfizer] announced that their vaccine, BNT162b2, turned out to be 95% effective against COVID-19, and resulted in no serious side effects.” essentials, like food and medicine.15 enrolled upwards of 30,000 particiTherefore, the immediate threat of the pants, and the first interim analysis repandemic will require trade-offs to be made for adequate vaccine distribution. With hopes that these hurdles will be effectively addressed, Pfizer and BioNTech expect to produce up to 50 million doses by the end of 2020 and up to 1.3 billion doses by the end of 2021. c vealed 95 cases of COVID-19 amongst volunteers, with 90 of these cases occurring in the placebo group, thus indicating a vaccine efficacy of 94.5%. Later, on November 30, Moderna

Shortly after Pfizer and BioNTech released their trailblazing news, Moderna, a biotechnology company based in Cambridge, Massachusetts, announced similarly hopeful results on November 16. Moderna’s vaccine candidate against COVID-19, mRNA-127, resulted in a 94.5% efficacy rate during the preliminary analysis of its Phase 3 trial, also known as the Coronavirus Efficacy and Safety Study (COVE) study. The COVE study is a collaboration between the National Institute of Allergy and Infectious Diseases (NAID) and the Biomedical Advanced Research and Development Authority (BARDA). It has announced a primary efficacy analysis of its Phase 3 COVE study, which revealed a 94.1% vaccine efficacy against COVID-19 and a 100% vaccine efficacy against severe COVID-19.18 No serious safety concerns related to mRNA-1273 were observed during the Phase 3 trial. In addition to these reports, Moderna requested an emergency use authorization (EUA) from the US FDA on November 30, and they are expected to hear back on December 17.18

Moderna’s vaccine employs mRNA technology similar to Pfizer and BioNTech. Despite the similarities in development, Moderna presents a vital advan-

tage in vaccine distribution. For shipping and long-term storage, mRNA-1273 must be kept at -20 oC, which is a standard temperature for freezers.19After thawing, it must be stored between 2oC and 8oC for up to 30 days, which is also a standard temperature range for refrigerators.19 These conditions are much more COVID-19 immunization, the question of who will get the vaccine first emerges as a prominent topic. On December 1, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) voted to prioritize health care workers and nurs-

ing medical conditions that categorize them as high-risk along with older adults in densely populated settings.22 Phase 3 makes up the largest portion of the population with essential service workers at a high risk of exposure, teachers and logistically feasible compared to BNT- ing home residents when vaccinations school staff, people in homeless shelters 162b2—but why is this the case when the vaccines utilize similar technologies? According to Moderna spokesperson Colleen Hussey, the answer lies in two factors. become available later this year. These as moderate-risk. However, it’s important to note that a vaccine alone will not resolve the current public health situation in the United States.” “ 22 and prisons, older adults who have not already been treated, and people with underlying conditions that categorize them Phase 4 consists of One, she explains, has to do with the vaccine’s “particular nanoparticle properties and structure.” The other reason is experience. Moderna has already developed ten mRNA vaccine candidates.20 Distributing Moderna’s vaccine to large populations will therefore be an easier task. However, the availability of more than one vaccine with such high efficacy rates provides a silver lining during the nation’s public health crisis.

With many people eager to receive a groups comprise approximately 24 million people, meaning that an estimated 48 million doses of the vaccine must be administered to effectively account for everyone.21 Furthermore, the US National Academies of Sciences, Engineering and Medicine (NASEM) has created a five-step guide with suggestions on a fair distribution of COVID-19 vaccines in the United States. The plan is divided into five phases, with Phase 1 consisting of healthcare workers and first responders. Phase 2 comprises people with underlyyoung adults, children, and essential service workers at increased risk of exposure, and Phase 5 is everyone else in the population.22

Groundbreaking advances are being made to control the spread of the coronavirus pandemic. The development of multiple COVID-19 vaccines within such a short time span is a historical achievement in the realm of science and will benefit the lives of billions of people. However, it’s important to note that a vaccine alone will not resolve the current public health situation in the United States. Especially in the midst of a holiday season, it’s inevitable that there are worse days to come. Thus, there must be continued efforts at practicing good personal hygiene, social distancing, and mask-wearing in order to overcome the nation’s biggest challenge of the century.

www

Maiya Hossain is a firstyear in Davenport College. She is a prospective HSHM major from Ohio. She can be contacted at maiya.hossain@yale.edu

Wikimedia Commons

Pfizer is one of the world’s largest pharmaceutical companies. Its headquarters are located in New York City.

REFERENCES

Why is Our Genome Data So White? A Discussion on the Lack of Representation in Genome-Wide Association Studies by Ann-Marie Abunyewa

1. Popejoy, A. & Fullerton, S. (2016, October 12). Genomics is failing on diversity. In Nature. Retrieved December 21, 2020, from https://www.nature.com/news/genomics-isfailing-on-diversity-1.20759#/ 2. Sirugo, G., Williams, S., & Tishkoff, S. (2019). The missing diversity in human genetic studies. Cell, 177(1), 26-31. https://doi.org/10.1016/j.cell.2019.02.048 3. Nature. (2020, September 1). Henrietta Lacks: Science must right a historical wrong. In Nature. Retrieved December 21, 2020, from https://www.nature.com/articles/d41586020-02494-z 4. Holland, B. (2018, December 4). The ‘Father of Modern Gynecology’ performed shocking experiments on enslaved women. In History. Retrieved December 21, 2020, from https://www.history.com/news/the-father-of-modern-gynecology-performedshocking-experiments-on-slaves 5. Rodriguez, M., & García, R. (2013). First, do no harm: The US sexually transmitted disease experiments in Guatemala. American Journal of Public Health, 103(12), 21222126. https://doi.org/10.2105/AJPH.2013.301520 6. Centers for Disease Control and Prevention. (2020, March 2). The Tuskegee timeline. In Centers for Disease Control and Prevention. Retrieved December 21, 2020, from https://www.cdc.gov/tuskegee/timeline.htm 7. Harmon, A. (2010, April 21). Indian tribe wins fight to limit research of its DNA. In New York Times. Retrieved December 21, 2020, from https://www.nytimes.com/2010/04/22/us/22dna.html 8. Bustamante, C., De La Vega, F. & Burchard, E. (2011). Genomics for the world. Nature, 475, 163-165. https://doi.org/10.1038/475163a 9. Jacewicz, N. (2016, June 16). Why are health studies so white? In The Atlantic. Retrieved December 21, 2020, from https://www.theatlantic.com/health/archive/2016/06/why-arehealth-studies-so-white/487046/ 10. Wendler, D., Kington, R., Madans, J. Van Wye, G., Christ-Schmidt, H., Pratt, L., Brawley, O., Gross, C., & Emanuel, E. (2005). Are racial and ethnic minorities less willing to participate in health research? PLOS Medicine, 3(2), e19. https://doi.org/10.1371/journal.pmed.0030019 11. Ashford, J. (2020, July 22). Clinical trials need to include more Black and other minority participants: Here’s how. In Stat. Retrieved December 21, 2020, from https://www.statnews.com/2020/07/22/clinical-trials-include-more-black-and-otherminority-participants/ 12. The All of Us Research Program Investigators. (2019). The All of Us research program. New England Journal of Medicine, 387(1), 668-676. https://doi.org/10.1056/NEJMsr1809937

The Doctor with a Gavel: Keeping the Gates to the Constitutional Right to Health in Brazil by Murlio Dorion

1. Constituição da República Federativa do Brasil de 1988, Assembleia constituinte, 1 (1988). 2. Medida Cautelar na petição: Pet 1246 SC, Min. Celso de Mello ___ (1997). https://stf. jusbrasil.com.br/jurisprudencia/21028211/medida-cautelar-na-peticao-pet-1246-sc-stf 3. Ferraz, O. L. M. (2019). Para equacionar a judicialização da saúde no Brasil. Revista Direito GV, 15(3). 4. Paixão, A. L. S. da. (2019). Reflexões sobre a judicialização do direito à saúdee suas implicações no SUS. Ciência & Saúde Coletiva, 24, 2167–2172. 5. SANTOS, B. I. de C., & ARTEIRO, R. L. (2011). O princípio contramajoritário como mecanismo regulamentador da soberania. I SIMPÓSIO INTERNACIONAL DE ANÁLISE CRÍTICA DO DIREITO DA UNIVERSIDADE ESTADUAL DO NORTE DO PARANÁ. 6. Vieira, F. S. (2020). Direito à saúde no Brasil: Seus contornos, judicialização e a necessidade da macrojustiça. 7. Agrg. No recurso extraordinário N. 271.286-8 Rio Grande do Sul, Min. Celso de Mello ___ (Supremo Tribunal Federal 2000). http://redir.stf.jus.br/paginadorpub/paginador. jsp?docTP=AC&docID=335538 8. Campos Neto, O. H., Acurcio, F. de A., Machado, M. A. de Á., Ferré, F., Barbosa, F. L. V., Cherchiglia, M. L., & Andrade, E. I. G. (2012). Médicos, advogados e indústria farmacêutica na judicialização da saúde em Minas Gerais, Brasil. Revista de Saúde Pública, 46, 784–790. 9. Gross, A. F. (2019). Desigualdade de acesso à saúde no Brasil e consequências redistributivas da judicialização. 10. Fonseca, M. G. P., Travassos, C., Bastos, F. I., Silva, N. do V., & Szwarcwald, C. L. (2003). Distribuição social da AIDS no Brasil, segundo participação no mercado de trabalho, ocupação e status sócio-econômico dos casos de 1987 a 1998. Cadernos de Saúde Pública, 19, 1351–1363. 11. Barroso, L. R. (2009). Da falta de efetividade à judicialização excessiva: Direito à saúde, fornecimento gratuito de medicamentos e parâmetros para a atuação judicial. 12. das Chagas, C. P., & dos Santos, F. P. (2018). Efeitos do gasto com a judicialização da saúde no orçamento da Secretaria Estadual de Saúde do Distrito Federal entre 2013 e 2017. CADERNOS IBERO-AMERICANOS DE DIREITO SANITÁRIO, 7(2), 147–172. 13. Nota Informativa no 006/2016—GAB/DDAHV/SVS/MS, (2016) (testimony of MINISTÉRIO DA SAÚDE). 14. Araujo, R. S., Souza, A. S. S. de, & Braga, J. U. (2020). A quem afetou o desabastecimento de penicilina para sífilis no Rio de Janeiro, 2013–2017? Revista de Saúde Pública, 54, 109. 15. Ribeiro, A. D. da C., Dan, C. de S., Santos, A. da S., Croda, J., & Simionatto, S. (2020). Neurosyphilis in Brazilian newborns: A health problem that could be avoided. Revista Do Instituto de Medicina Tropical de São Paulo, 62. 16. GBD Diarrhoeal Diseases Collaborators. (2017). Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Infectious Diseases, 17(9), 909–948. PubMed. https://doi.org/10.1016/S1473-3099(17)30276-1 17. Repercussão Geral: Recurso Extraordinário 566.471 Rio Grande do Norte, Min. Marco Aurélio ___ (Supreme Federal Court 2010). http://www.stf.jus.br/arquivo/cms/ noticiaNoticiaStf/anexo/RE566471.pdf

The Rise of an Unlikely Public Health Ally: Brazilian Drug Cartels by Sophia de Olivera

1. Brazil. (n.d.). Retrieved December 20, 2020, from https://www.worldometers.info/coronavirus/country/brazil/ 2. Walsh, N., Shelley, J., Fortuna, R., & Bonnett, W. (2020, June 13). Rio cartels go from running drugs to pushing medication. Retrieved December 20, 2020, from https://www.cnn.com/2020/06/13/americas/brazil-rio-favela-coronavirus-care/index.html 3. Staff, S. (2020, August 03). Virus exposes cracks in Brazil's public health system. Retrieved December 20, 2020, from https://medicalxpress.com/news/2020-08-virus-exposes-brazil-health.html 4. Brazil gangs impose strict curfews to slow coronavirus spread. (2020, March 25). Retrieved December 20, 2020, from https://www.theguardian.com/world/2020/mar/25/brazil-rio-gangscoronavirus 5. Thelwell, K. (2020, August 08). COVID-19 Unites Brazil's Favelas. Retrieved December 20, 2020, from https://borgenproject.org/covid-19-unites-brazils-favelas/

COVID-19 and Mental Health: Sleep, Anxiety, and Suicide by Mika Yokota

1. Statement from WHO. (2020, April 27). Archived: WHO Timeline - COVID-19. World Health Organization. https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19. 2. Khan Academy. Sleep stages and circadian rhythms (video). Khan Academy. https://www.khanacademy.org/test-prep/mcat/processing-the-environment/sleep-andconsciousness/v/sleep-stages-and-circadian-rhythms. 3. Stress Hormones: The 4 Major Stress Hormones. Its Psychology. (2017, July 15). https://itspsychology.com/stress-hormones/. 4. Sher, L. (2020). The impact of the COVID-19 pandemic on suicide rates. QJM: An International Journal of Medicine. https://doi.org/10.1093/qjmed/hcaa202 5. Huang, Y., & Zhao, N. (2020). Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 epidemic in China: a web-based cross-sectional survey. Elsevier Psychiatry Research , 288. https://doi.org/10.1101/2020.02.19.20025395 6. Huang, Y., & Zhao, N. (2020). Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 epidemic in China: a web-based cross-sectional survey. Elsevier Psychiatry Research , 288. https://doi.org/10.1101/2020.02.19.20025395 7. Liu, Q., Luo, D., Haase, J. E., Guo, Q., Wang, X. Q., Liu, S., … Yang, B. X. (2020). The experiences of health-care providers during the COVID-19 crisis in China: a qualitative study. The Lancet Global Health, 8(6). https://doi.org/10.1016/s2214-109x(20)30204-7 8. Liu, Q., Luo, D., Haase, J. E., Guo, Q., Wang, X. Q., Liu, S., … Yang, B. X. (2020). The experiences of health-care providers during the COVID-19 crisis in China: a qualitative study. The Lancet Global Health, 8(6). https://doi.org/10.1016/s2214-109x(20)30204-7 9 .Buysse, D. J. (2013). Insomnia. Jama, 309(7), 706. https://doi.org/10.1001/jama.2013.193 10. Lai, J., Ma, S., Wang, Y., Cai, Z., Hu, J., Wei, N., … Hu, S. (2020). Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Network Open, 3(3). https://doi.org/10.1001/jamanetworkopen.2020.3976 11. Sher, L. (2020). COVID-19, anxiety, sleep disturbances and suicide. Sleep Medicine, 70, 124. https://doi.org/10.1016/j.sleep.2020.04.019 12. Huang, Y., & Zhao, N. (2020). Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 epidemic in China: a web-based cross-sectional survey. Elsevier Psychiatry Research , 288. https://doi.org/10.1101/2020.02.19.20025395 13. Daniel, S. J. (2020). Education and the COVID-19 pandemic. Prospects. https://doi.org/10.1007/s11125-020-09464-3

Mass Incarceration and COVID-19 by Amma Otchere

1. Responses to the COVID-19 pandemic. (2020, December 14). Prison Policy Initiative. Retrieved from https://www.prisonpolicy.org/virus/virusresponse.html. 2. Walmsley, R. (2016). World Prison Population List: Eleventh Edition. World Prison Brief and Institute for Crime & Justice Poly Research. Retrieved from https://www.prisonstudies.org/sites/default/files/resources/downloads/world_prison_ population_list_11th_edition_0.pdf. 3. de Oliveira Andrade, R. (2020). Covid-19: Prisons exposed in Brazil’s Crisis. British Medical Journal, 370, m2884. 4. Tharoor, I. (2020). Brazil’s Bolsonaro popular as ever, no matter his handling of the coronavirus. Washington Post. Retrieved from https://www.washingtonpost.com/ world/2020/12/16/brazil-coronavirus-bolsonaro-popularity/. 5. Khoza, A. (2020). How South African prisons are managing Covid-19. New Frame. Retrieved from https://www.newframe.com/how-south-african-prisons-are-managingcovid-19/. 6. Macmadu, A., Berk, J., Kaplowitz, E., Mercedes, M., Rich, J.D., & Brinkley-Rubinstein, L. (2020). COVID-19 and mass incarceration: a call for urgent action. Lancet, 5(11), E571-E572. 7. Gale, J., Lee, H., & Hull, D. (2020). As COVID-19 roars through U.S. jails, South Korea may provide template. The Japan Times. Retrieved from https://www.japantimes.co.jp/ news/2020/11/26/asia-pacific/coronavirus-us-prisons-south-korea/.

8. New York Times Editorial Board. (2020). America Is Letting the Coronavirus Rage Through Prisons. New York Times. Retrieved from https://www.nytimes.com/2020/11/21/ opinion/sunday/coronavirus-prisons-jails.html?auth=login-google. 9. Anderson, K.M., Olson, S. (Eds.). (2019). Mass Incarceration as a Public Health Issue. The Effects of Incarceration and Reentry on Community Health and Well-Being: Proceedings of a Workshop. National Academies Press. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK555719/. 10. Soucheray, S. (2020). US blacks 3 times more likely than whites to get COVID-19. University of Minnesota Center for Infectious Disease Research and Policy. Retrieved from https://www.cidrap.umn.edu/news-perspective/2020/08/us-blacks-3-times-morelikely-whites-get-covid-19. 11. King, P.T., Cormack, D., & Keenan, R. (2020). COVID-19 and the mass incarceration of Indigenous peoples. Journal of Indigenous Social Development, 9(3), 141-157. 12. Republic of South Korea. (2020, June 30). World Prison Brief. Retrieved from https://www.prisonstudies.org/country/republic-south-korea.

On Average, What People Think About Covid-19 Responses, and the New Vaccine by Ryan Bose-Roy

1. Fadda, M., Albanese, E., & Suggs, L. (n.d.). When a COVID-19 vaccine is ready, will we all be ready for it? Retrieved December 23, 2020, from https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC7288619/. 2. Tompkins, S. (2020, December 22). The arrival of the Moderna vaccine brings hope to rural areas. Retrieved December 23, 2020, from https://www.nytimes.com/live/2020/12/21/world/ covid-19-coronavirus/the-arrival-of-the-moderna-vaccine-brings-hope-to-rural-areas. 3. European Commission Authorizes Pfizer’s Coronavirus Vaccine. (2020, December 21). Retrieved December 23, 2020, from https://www.usnews.com/news/health-news/ articles/2020-12-21/european-commission-authorizes-pfizers-coronavirus-vaccine. 4. More Than 2.7 Million People Have Gotten Vaccines: Covid-19 Tracker. (n.d.). Retrieved December 23, 2020, from https://www.bloomberg.com/graphics/covid-vaccine-trackerglobal-distribution/?sref=aGTrSb9U 5. Jon CohenNov. 11, 2., Lucy HicksDec. 21, 2., Lucy HicksDec. 17, 2., Lucy HicksDec. 16, 2., Lucy HicksDec. 10, 2., & Lucy HicksDec. 4, 2. (2020, November 12). Russia’s claim of a successful COVID-19 vaccine doesn’t pass the ‘smell test,’ critics say. Retrieved December 23, 2020, from https://www.sciencemag.org/news/2020/11/russia-s-claim-successful-covid19-vaccine-doesn-t-pass-smell-test-critics-say. 6. Mandavilli, A. (2020, December 20). The Coronavirus Is Mutating. What Does That Mean for Us? Retrieved December 23, 2020, from https://www.nytimes.com/2020/12/20/health/ coronavirus-britain-variant.html?action=click. 7. Landler, M., & Castle, S. (2020, December 21). Concerns About Coronavirus Variant Cut Off U.K. From Europe. Retrieved December 23, 2020, from https://www.nytimes. com/2020/12/21/world/europe/coronavirus-variant-uk.html?action=click 8. Gan, N. (2020, December 19). How India plans to vaccinate 300 million people against Covid-19. Retrieved December 23, 2020, from https://www.cnn.com/2020/12/18/asia/indiacoronavirus-vaccine-intl-hnk/index.html. 9. Mullard, A. (2020, November 30). How COVID vaccines are being divvied up around the world. Retrieved December 23, 2020, from https://www.nature.com/ articles/d41586-020-03370-6. 10. Kitroeff, N. (2020, December 21). Mexico Misled Citizens About the Severity of Coronavirus in its Capital. Retrieved December 23, 2020, from https://www.nytimes. com/2020/12/21/world/americas/mexico-city-covid.html. 11. Reinhart, R. (2020, December 21). More Americans Now Willing to Get COVID-19 Vaccine. Retrieved December 23, 2020, from https://news.gallup.com/poll/325208/americanswilling-covid-vaccine.aspx. 12. Opam, K. (2020, November 17). Americans Are More Willing to Take a Coronavirus Vaccine, Poll Suggests. Retrieved December 23, 2020, from https://www.nytimes. com/2020/11/17/health/gallup-poll-coronavirus-vaccine.html. 13. Opam, K. (2020, November 17). Americans Are More Willing to Take a Coronavirus Vaccine, Poll Suggests. Retrieved December 23, 2020, from https://www.nytimes. com/2020/11/17/health/gallup-poll-coronavirus-vaccine.html. 14. Public assessments of the U.S. coronavirus outbreak. (2020, August 26). Retrieved December 23, 2020, from https://www.pewresearch.org/politics/2020/08/06/publicassessments-of-the-u-s-coronavirus-outbreak/. 15. Darrough, C., & Adib, D. (2020, December 4). Health experts on COVID-19 vaccine: Americans have ‘a lot of distrust’. Retrieved December 23, 2020, from https://abcnews. go.com/Health/health-experts-covid-19-vaccine-americans-lot-distrust/story?id=74519119. 16. Dryhurst, S. (2020, May 5). Risk perceptions of COVID-19 around the world. Retrieved December 23, 2020, from https://www.tandfonline.com/doi/full/10.1080/13669877.2020.1758193. 17. Fetzer, T., Witte, M., Hensel, L., Jachimowicz, J., Haushofer, J., Ivchenko, A., … Yoeli, E. (2020, April 16). Perceptions of an Insufficient Government Response at the Onset of the COVID-19 Pandemic are Associated with Lower Mental Well-Being. https://doi. org/10.31234/osf.io/3kfmh. 18. Al-Dossary, R., Alamri, M., Albaqawi, H., Al Hosis, K., Aljeldah, M., Aljohan, M., . . . Almazan, J. (2020, November 9). Awareness, Attitudes, Prevention, and Perceptions of COVID-19 Outbreak among Nurses in Saudi Arabia. Retrieved December 23, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664870/.

A COVID-19 Vaccine: What’s Been Done and What’s to Come by Maiya Hossain

1. Kochhar, R. (2020, August 26). Unemployment rose higher in three months of COVID-19 than it did in two years of the Great Recession. Retrieved December 06, 2020, from https://www.pewresearch.org/fact-tank/2020/06/11/unemployment2. Get the facts about a COVID-19 (coronavirus) vaccine. (2020, December 03). Retrieved December 06, 2020, from https://www.mayoclinic.org/diseasesconditions/coronavirus/in-depth/coronavirus-vaccine/art-20484859 3. Secretary, H., & Assistant Secretary for Public Affairs (ASPA). (2020, November 30). Fact Sheet: Explaining Operation Warp Speed. Retrieved December 06, 2020, from https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html 4. Soucheray, S. (2020, June 04). Operation Warp Speed names 5 COVID-19 vaccine candidates. Retrieved December 06, 2020, from https://www.cidrap.umn.edu/newsperspective/2020/06/operation-warp-speed-names-5-covid-19-vaccine-candidates 5. Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study. (2020, July 27). Retrieved December 06, 2020, from https://www.pfizer.com/news/press-release/press-release-detail/ pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0 6. Zimmer, C., & Thomas, K. (2020, November 18). Pfizer’s Covid Vaccine: 11 Things You Need to Know. Retrieved December 06, 2020, from https://www. nytimes.com/live/2020/pfizer-covid-19-vaccine 7. Get the Facts on Our COVID-19 Vaccine Candidates. (2020, May 05). Retrieved December 06, 2020, from https://www.pfizer.com/news/hot-topics/get_the_facts_ on_our_covid_19_vaccine_candidates 8. Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. (2020, November 09). Retrieved December 06, 2020, from https://www.pfizer.com/news/press-release/ press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against 9. Callaway, E. (2020, November 09). What Pfizer’s landmark COVID vaccine results mean for the pandemic. Retrieved December 06, 2020, from https://www. nature.com/articles/d41586-020-03166-8 10. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. (2020, November 18). Retrieved December 06, 2020, from https://www.pfizer.com/news/press-release/press-release-detail/ pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine 11. Thomas, K. (2020, November 18). New Pfizer Results: Coronavirus Vaccine Is Safe and 95% Effective. Retrieved December 06, 2020, from https://www.nytimes. com/2020/11/18/health/pfizer-covid-vaccine.html 12. Center for Drug Evaluation and Research. (2020, June 30). Coronavirus (COVID-19) Update: FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines. Retrieved December 06, 2020, from https:// www.fda.gov/news-events/press-announcements/coronavirus-covid-19-updatefda-takes-action-help-facilitate-timely-development-safe-effective-covid 13. Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine. (2020, November 20). Retrieved December 06, 2020, from https://www.pfizer.com/news/press-release/press-release-detail/pfizerand-biontech-submit-emergency-use-authorization 14. Saey, T. (2020, December 03). The ‘last mile’ for COVID-19 vaccines could be the biggest challenge yet. Retrieved December 06, 2020, from https://www.sciencenews. org/article/covid19-coronavirus-vaccine-last-mile-logistics-pfizer-moderna 15. Saey, T. (2020, November 21). Here’s why COVID-19 vaccines like Pfizer’s need to be kept so cold. Retrieved December 06, 2020, from https://www.sciencenews. org/article/coronavirus-covid-19-why-vaccines-cold-freeze-pfizer-moderna 16. Hinshaw, D., & Deng, C. (2020, December 04). Race to Vaccinate World Against Covid-19 Intensifies. Retrieved December 06, 2020, from https://www.wsj.com/ articles/race-to-vaccinate-world-against-covid-19-intensifies-11607111607 17. Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study. (2020, November 16). Retrieved December 06, 2020, from https://investors.modernatx.com/news-releases/newsrelease-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy 18. Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization. (2020, November 30). Retrieved December 06, 2020, from https://investors.modernatx.com/news-releases/news-release-details/modernaannounces-primary-efficacy-analysis-phase-3-cove-study 19. Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures. (2020, November 16). Retrieved December 06, 2020, from https://investors.modernatx.com/news-releases/news-release-details/ moderna-announces-longer-shelf-life-its-covid-19-vaccine 20. Simmons-Duffin, S. (2020, November 17). Why Does Pfizer’s COVID-19 Vaccine Need To Be Kept Colder Than Antarctica? Retrieved December 06, 2020, from https://www.npr.org/sections/health-shots/2020/11/17/935563377/why-doespfizers-covid-19-vaccine-need-to-be-kept-colder-than-antarctica 21. Huang, P. (2020, December 01). Health Care Workers, Nursing Home Residents To Be Prioritized For COVID-19 Vaccine. Retrieved December 06, 2020, from https://www.npr.org/sections/health-shots/2020/12/01/940700204/should-nursinghome-residents-be-prioritized-for-getting-the-covid-19-vaccine 22. Subbaraman, N. (2020, September 17). Who gets a COVID vaccine first? Access plans are taking shape. Retrieved December 06, 2020, from https://www.nature. com/articles/d41586-020-02684-9